Mary Gardner, has over 25 years’ experience in the Life Science Industry. She is the founder and inventor of DelNova core assets since 2016; bootstrapped and led the company through its early research phase and into its Series A financing.
Mary has been a mentor for early stage life science companies since 2014, with CONNECT and MATTER; both startup company accelerators in the greater San Diego and Chicago areas, respectively. As former Director of Technology Assessment with, Hospira, a Pfizer company (~11 yrs) she was responsible for the front end of innovation, including supporting business development via the sourcing & evaluation of external new technology and product opportunities to generate future topline growth in healthcare products (pharmaceuticals, drug delivery and medical devices). Experienced in the healthcare & biotechnology industries including positions in consulting, process design engineering and project management.
Prior to joining Hospira, Mary led the Business Development office of The Lawson Health Research Institute & London Health Sciences Centre, London Ontario. Here she was responsible for the managing the IP portfolio, technology transfer & spin-off companies created from innovations arising from leading Canadian teaching hospitals.
Mary is a Certified Licensing Professional (CLP), she has an MBA (finance major) from McMaster University, Hamilton and a BEngSc (Chemical & Biochemical) from the University of Western Ontario, London, Canada.
Dan Bradbury is a Life Sciences Executive with over 35 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm and Chief Executive Officer, Chairman and Co-Founder of Equillium, Inc., a biopharmaceutical company based in La Jolla, CA, focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need.
Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Biocon Limited (NSE: BIOCON), Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Biolinq, Inc. (Private), Castle Biosciences, Inc. (Private), DiaVacs, Inc. (Private), Equillium, Inc. (Private), Liquid Grids, Inc. (Private), NeuroVia, Inc. (Private), ProSciento, Inc. (Private), Renova Therapeutics (Private) and Sensulin, Inc. (Private). He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board and the Arctic Aurora Life Science Advisory Board.
Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Dr Ed Ogunro has more than 25 years of product development and management experience in the healthcare industry and is highly experienced in the development of medical devices, generic and branded pharmaceuticals.
Ed is the former Senior Vice President and Chief Scientific Officer of Hospira, a Specialty Pharmaceutical and Medical Device company based in Lake Forest, IL which was spun out of Abbott Laboratories, North Chicago, IL in 2004 and later acquired by Pfizer in 2015. Prior to its acquisition by Pfizer Hospira was the world’s largest producer of generic injectable pharmaceuticals. He led the transition of the Hospital Products focused R&D, Medical and Regulatory Affairs organization from Abbott into an independent company and oversaw the initiation of several key programs including biosimilars, generic pharmaceuticals, integrated infusion therapy products and medication management systems. He retired from Hospira in 2007. Prior to Hospira, he was Corporate Vice President of R&D, Medical and Regulatory Affairs in the Hospital Products Division of Abbott Laboratories and Divisional Vice President in the Abbott Diagnostics Division. During his 22-year tenure in the Diagnostics division he launched several key products including AxSym and Architect, two of the most successful immunoassay analysers in the Diagnostics industry. He serves on the board of directors of Luminex, Inc (NASDAQ: LMNX).
Ed received his Bachelor of Science degree in Physiology and Biochemistry from Reading University, UK and his Doctorate in Biochemistry from London University, UK.
Rebekah Fleming, PhD, is a neurobiologist with broad experience in neuron physiology and neurotransmitter receptor pharmacology. She holds a BA in Physics from Grinnell College and completed multidisciplinary graduate training in the Department of Biomedical Engineering, the Curriculum in Neurobiology, and the Bowles Center for Alcohol Studies at The University of North Carolina at Chapel Hill. After earning her PhD, she moved on to postdoctoral studies in the Department of Psychiatry and Behavioral Sciences at Duke University and at the Durham Veterans Affairs Medical Center. Dr. Fleming received a Career Development Award from the Department of Veterans Affairs. She became an Assistant Professor in the Addiction Division of the Duke Psychiatry Department, successfully competed for research funding, and managed her own basic science research laboratory at the Durham VA. Since transitioning to industry in 2016, she has held several positions as a science and medical writer and consultant. She has helped small pharmaceutical companies to win over $6 M in federal grant funding.
Anindita Sarkar (Ani) has a rich experience in commercializing innovations.
As a Manager of Springboard Accelerator Program and Innovation Research at CONNECT, she revitalized the program. She engaged with startups from Life Sciences and Tech sectors. She guided them to maximize opportunities to attract investment, talent, and partnerships. Her clients acknowledge her for attracting angel investment of $3M and recruiting ten C-Suite executives in early-stage startups.
Prior to that, as a Post-doctoral researcher at Scripps Institution of Oceanography, she engaged with multiple teams. She supported the teams in building business cases for their inventions/discoveries. She also engaged with Life Sciences startups to evaluate market opportunities and competitive product positioning.
Currently, she is supporting the Tech Transfer Office at San Diego State University. She is also a project manager for ThinkingNode, an AI startup. The startup provides a general-purpose AI reasoning computing system to accelerate problem-solving in research and development.
Ani received PhD in Microbiology from Friedrich Schiller University, Germany. M.Sc. in Industrial Microbiology and B.Sc. in Microbiology from Devi Ahilya University, India. She also has a Professional Certificate in Finance from UC San Diego.
Dimas Jiménez, MBA, Chief Financial Officer. Mr. Jiménez received his MBA from Stanford’s Graduate School of Management, his BA from Dartmouth College and has earned the CFA, Chartered Financial Analyst designation. He has worked for Wall Street and Life Science firms for two decades. Prior to joining StemoniX, He was CFO at Orphagen Pharmaceuticals, VP Finance and Administration at Spinal Modulation, Controller at Pearl Therapeutics, and a Portfolio Manager at JP Morgan. Mr. Jiménez has led the acquisition of two of his companies including the ~$450M purchase of Spinal Modulation by St. Jude Medical.